Jefferies Maintains Buy Rating On Orthofix

According to Jefferies, Orthofix Int'l (NASDAQ: OFIX) posted an overall in-line quarter, as weakness in spine stimulation was offset by upside in orthopedics.

Jefferies said that the company announced significant progress toward settlement with the spine stimulation DOJ and FCPA investigations, which have been notable overhangs on OFIX shares. “With continued operating profitability improvement, we maintain our Buy rating.”

Orthofix closed yesterday at $33.74.